Ryan Specialty Holdings heads into its July 30 earnings print with analyst upgrades still flowing, short interest quietly rebuilding, and a stock that has already given back a little of its recent surge — a setup where the data pulls in more than one direction.
The analyst story this week has a new chapter. Piper Sandler lifted its target to $44 from $40 on July 15, keeping a Neutral. JP Morgan's Pablo Singzon raised his target to $39 from $37 on July 13 — still below the current price of $41.18, maintaining Underweight. Wells Fargo made the most aggressive move, pushing its target from $31 to $39 earlier in the week. The pattern across all ten firms that have acted in the past ten days is the same: targets up, ratings unchanged. The mean target now stands at $45.63, a modest 10.8% above the current price. That gap has widened slightly from last week's $44.29 mean, but it remains thin relative to the 15% one-month gain in the stock. Bulls at UBS and KBW still see room to $50 and $48 respectively. The Neutral and Underweight cluster — JP Morgan, Piper Sandler, Wells Fargo, Mizuho, Cantor Fitzgerald — is more cautious about valuation at these levels, even after raising numbers.
Short interest tells a less comfortable story for longs. Shorts added roughly 4% to their position over the past week, bringing SI to 11.5% of the free float — that is a genuinely elevated reading for an insurance broker. The daily history shows a step-change in mid-June: from around 12.5 million shares short to 14.8 million now, a build that has been gradual but persistent. What keeps this from feeling like a squeeze setup is the lending market. Cost to borrow has fallen sharply — down 18% on the week and 34% over the past month to just 0.54%. Availability has loosened considerably, with the availability ratio moving from a tight 88% at the June 29 peak to 128% now, meaning there are roughly 1.3 shares available to borrow for every share already short. Shorts are not paying up, and the lending pool is not under pressure. That argues for a deliberate, low-cost bet against the stock rather than a crowded trade approaching a squeeze.
Options positioning meanwhile leans distinctly bullish. The put/call ratio has dropped to 0.55, well below its 20-day average of 0.80, a reading that reflects call-side demand dominating. The PCR has been in this lower range consistently since late June, after spending early June closer to 2.0 — a sharp reversal in options sentiment that broadly mirrors the stock's own move higher. With the z-score around -0.54, the current reading is not an extreme, but the direction of travel has been clear. Options traders are not hedging into earnings the way they were six weeks ago.
The ownership picture adds a longer-dated context. Founder and Executive Chairman Patrick Ryan's $3.9 million open-market purchase at $32.50 in early June — with the CFO and General Counsel buying alongside — was the most definitive signal from inside the company that management viewed the mid-$30s as deeply discounted. The stock is now $41.18, so those buyers are sitting on roughly 27% paper gains. Institutional concentration is notable: Patrick Ryan holds 10.7% of shares, BlackRock holds 8.4%, and Neuberger Berman reported a large addition of 2.24 million shares through June 30. The bear case — declining property and casualty rates, compressed organic growth guidance, a restructuring charge running through 2028 — has not gone away, and the ORTEX factor scores flag this clearly: EPS surprise ranks in the 13th percentile and the 90-day EPS momentum score is just 6. Short sellers appear to be leaning into exactly that gap between a stock that has re-rated on hopes and a fundamental trajectory that has yet to confirm them.
The April 30 earnings print offers a sobering reference point: the stock fell 12.6% the next day and was still down 10% five days later. With shorts rebuilt, borrowing cheap, and the mean analyst target only 10% above the current price, the July 30 number will need to do genuine work to resolve the tension between a founder who bought aggressively at $32 and a short interest that has quietly grown to its highest level in months.
See the live data behind this article on ORTEX.
Open RYAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
